Uncategorized

India’s pharmaceutical industry is advancing toward high-science, innovation-driven Active Pharmaceutical Ingredient (API) development as HRV Pharma and Shodhana Laboratories announced a strategic multi-year Contract Development and Manufacturing (CDMO) partnership to accelerate next-generation API development.   The collaboration integrates HRV Pharma’s AI-enabled virtual API platform, regulatory expertise, and global market access with Shodhana Laboratories’ strengths in […]

The global pharmaceutical manufacturing landscape is witnessing a major investment as Eli Lilly and Company announced plans to build a $6 billion manufacturing facility dedicated to Active Pharmaceutical Ingredients (APIs). This development underscores the company’s commitment to strengthening domestic API production and advancing next-generation pharmaceutical manufacturing.   Expanding API Manufacturing Capacity The new facility will

India’s pharmaceutical sector is undergoing a structural shift as the government intensifies its focus on reducing import dependency for Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), and Drug Intermediates (DIs). As per the latest update released on March 13, 2026 by the Press Information Bureau (PIB), the Production Linked Incentive (PLI) Scheme for Bulk

Canada’s pharmaceutical and life sciences ecosystem is witnessing strong momentum as Applied Pharmaceutical Innovation (API) outlined key developments in its API Newsletter published on February 24, 2026. The update highlights advancements in domestic manufacturing, strategic partnerships, and infrastructure expansion aimed at strengthening Canada’s position in critical medicines production.   Scaling Domestic Manufacturing Capabilities A major

India’s pharmaceutical ingredient sector is gaining momentum through focused industry platforms as the API Connect Conference 2026 brought together key stakeholders across the API and formulation value chain. Held on January 22, 2026, the inaugural edition of the conference highlighted India’s growing importance as a global hub for Active Pharmaceutical Ingredients (APIs) and pharmaceutical manufacturing.

India’s Active Pharmaceutical Ingredient (API) industry is solidifying its position as a global manufacturing hub, driven by cost efficiency, regulatory excellence, and technological innovation. According to insights published on April 16, 2026 by Chemox Pharma, India continues to strengthen its role as the “Pharmacy of the World” amid rising global demand for affordable and high-quality

India’s Active Pharmaceutical Ingredient (API) industry is calling for stronger policy support as manufacturers urge the government to introduce import curbs and financial assistance for Good Manufacturing Practices (GMP) upgrades in the upcoming Union Budget 2026. According to a report published on January 23, 2026, the sector is facing rising compliance costs and increasing competition

India’s pharmaceutical sector is witnessing strategic consolidation as Gujarat-based Anlon Healthcare announced its move beyond Active Pharmaceutical Ingredients (APIs) through the acquisition of a majority stake in Remember India Health Links. The development, reported on April 17, 2026, marks a significant step toward building an integrated pharmaceutical business model. The company has approved the acquisition

Escalating Health Issues and API The Active Pharmaceutical Ingredients (API) market is increasing constantly, as it is a crucial active raw material used in medicines to determine their strength, dosage and effectiveness, which is important in the treatment of chronic diseases, including cardiovascular disorders, diabetes, and cancer. And the stats regarding the rise in these types